[ad_1]
CAMBRIDGE, Mbad., March 26, 2019 / PRNewswire / – In recent years, more and more evidence has shown links between cancer and obesity. In fact, obesity plays a role in nearly 20% of all cancer deaths and is a determinant of survival for many common cancers. There is no therapeutic solution to this problem – and so far, medical research professionals have had no way of getting the most up-to-date information.
A new area of research called "metabo-oncology" explains how obesity and metabolic dysfunctions (eg, prediabetes, T2D) lead to worse outcomes for cancer patients. Today, a coalition of academics, researchers, clinical oncologists and biotech leaders has launched Metabo-oncology.com. The Central Portal website serves as an organized resource for physicians and researchers to share ideas and research on this topic.
"This is really one of the biggest challenges I face every day in my practice of bad cancer," said one site contributor. Joyce A. O. Shaughnessy, M.D., president of Breast Cancer Research at the Texas Oncology-Cancer Center Baylor's Charles A. Sammons of Texas and President of the US Oncology Network. "We need to step up our efforts to provide our cancer patients with proven tools that will help them improve their metabolic health."
"Cancer patients with tumors sensitive to metabolic hormones such as insulin and leptin have a different type of cancer, which is why immunotherapies and targeted therapies do not usually work for these patients," he said. added James Shanahan, Co-Founder and Commercial Director of Sponsor Site SynDevRx, Inc. "Pharma needs to take into account the impact of the patient's systemic metabolic health to improve its response rate."
In an era marked by an aging population and increasing rate of obesity, Metabo-oncology.com presents the latest research and commentary from renowned experts in order to foster collaboration in this emerging field. The site offers links to leading journals, including: Nature, The journal of immunology, The lancet and Nature Cell Biology. It is organized to help newcomers to metabo-oncology research easily navigate the epidemiology, medical concerns and scientific understandings of the mechanisms underlying the "cancer-obesity link".
Metabo-Oncology.com will evolve over time to provide viable options for clinical oncologists and the latest research for researchers, as well as information on medical treatments, including exercise, diet and nutrition .
For more information, visit Metabo-oncology.com.
Contact:
James Shanahan
Co-Founder, Director of Business and Director at SynDevRx
617- 401-3110
[email protected]
SOURCE SynDevRx, Inc.
Related Links
http://syndevrx.com/
Source link
